[8-K] Summit Therapeutics Inc. Reports Material Event
Summit Therapeutics Inc. disclosed that it furnished a press release announcing its financial results and operational progress for the quarter ended June 30, 2025. The press release is provided as Exhibit 99.1 to this Current Report and is incorporated by reference into Item 2.02.
The filing clarifies that the exhibit is being furnished, not filed, and therefore is not subject to Section 18 liability and is not automatically incorporated by reference into other Securities Act or Exchange Act filings except by specific reference. The company鈥檚 common stock trades under the ticker SMMT on The Nasdaq Stock Market.
Summit Therapeutics Inc. ha comunicato di aver diffuso un comunicato stampa relativo ai risultati finanziari e agli aggiornamenti operativi per il trimestre chiuso il 30 giugno 2025. Il comunicato 猫 allegato come Exhibit 99.1 al presente Current Report ed 猫 richiamato per incorporazione nell'Item 2.02.
Il deposito chiarisce che l'allegato 猫 fornito, non presentato, e pertanto non 猫 soggetto alla responsabilit脿 prevista dalla Sezione 18 e non viene automaticamente incorporato per riferimento in altri documenti ai sensi del Securities Act o dell'Exchange Act, salvo esplicita richiamazione. Le azioni ordinarie della societ脿 sono quotate con il simbolo SMMT sul Nasdaq Stock Market.
Summit Therapeutics Inc. inform贸 que public贸 un comunicado de prensa con sus resultados financieros y avances operativos del trimestre cerrado el 30 de junio de 2025. El comunicado se adjunta como Exhibit 99.1 a este Current Report y se incorpora por referencia en el 铆tem 2.02.
La presentaci贸n aclara que el anexo se est谩 proporcionando, no presentando, y por ello no est谩 sujeto a la responsabilidad prevista en la Secci贸n 18 ni se incorpora autom谩ticamente por referencia en otros documentos amparados por el Securities Act o el Exchange Act, salvo menci贸n expresa. Las acciones ordinarias de la compa帽铆a cotizan bajo el s铆mbolo SMMT en The Nasdaq Stock Market.
Summit Therapeutics Inc.電� 2025雲� 6鞗� 30鞚茧 毵堦皭霅� 攵勱赴鞚� 鞛 鞁れ爜 氚� 鞖挫榿 歆勴枆 靸來櫓鞚� 鞎岆Μ電� 氤措弰鞛愲毳� 氚滍憸頄堧嫟瓿� 氚濏様鞀惦媹雼�. 頃措嫻 氤措弰鞛愲電� 氤� Current Report鞐� Exhibit 99.1搿� 鞝滉车霅橃棃鞙茧┌ 頃 2.02鞐� 鞚橅暣 彀胳“霅橃柎 韽暔霅╇媹雼�.
頃措嫻 鞝滌稖靹滊姅 觳秬氍检澊 鞝滌稖霅� 瓴冹澊 鞎勲媹霛� 鞝滉车霅� 瓴�鞛勳潉 氇呿檿頌� 頃橂┌, 霐半澕靹� 靹轨厴 18鞚� 毂呾瀯 雽�靸侅澊 鞎勲媹瓿� 氇呾嫓鞝� 彀胳“臧� 鞐嗠姅 頃� Securities Act 霕愲姅 Exchange Act鞚� 雼るジ 氍胳劀鞐� 鞛愲彊鞙茧 彀胳“霅橃柎 韽暔霅橃 鞎婌姷雼堧嫟. 須岇偓鞚� 氤错喌欤茧姅 雮橃姢雼� 歃濌秾瓯半灅靻岇棎靹� SMMT 旮绊樃搿� 瓯半灅霅╇媹雼�.
Summit Therapeutics Inc. a d茅clar茅 avoir diffus茅 un communiqu茅 de presse pr茅sentant ses r茅sultats financiers et ses progr猫s op茅rationnels pour le trimestre clos le 30 juin 2025. Le communiqu茅 est fourni en tant que Exhibit 99.1 dans ce Current Report et y est incorpor茅 par r茅f茅rence 脿 l'Item 2.02.
Le d茅p么t pr茅cise que la pi猫ce jointe est fournie, non d茅pos茅e, et n'est donc pas soumise 脿 la responsabilit茅 pr茅vue par la Section 18 et n'est pas automatiquement incorpor茅e par r茅f茅rence dans d'autres documents en vertu du Securities Act ou de l'Exchange Act, sauf renvoi explicite. Les actions ordinaires de la soci茅t茅 sont cot茅es sous le symbole SMMT au Nasdaq.
Summit Therapeutics Inc. gab bekannt, eine Pressemitteilung zu den Finanzergebnissen und operativen Fortschritten f眉r das zum 30. Juni 2025 endende Quartal ver枚ffentlicht zu haben. Die Pressemitteilung ist diesem Current Report als Exhibit 99.1 beigef眉gt und wird durch Verweisung in Punkt 2.02 aufgenommen.
Die Einreichung stellt klar, dass die Anlage bereitgestellt, nicht eingereicht wird und daher nicht der Haftung nach Abschnitt 18 unterliegt und nicht automatisch durch Verweisung in andere Unterlagen gem盲脽 dem Securities Act oder dem Exchange Act einbezogen wird, es sei denn durch ausdr眉ckliche Bezugnahme. Die Stammaktien des Unternehmens werden unter dem Tickersymbol SMMT an der Nasdaq gehandelt.
- Press release furnished publicly announcing Q2 2025 financial results and operational progress (Exhibit 99.1).
- Disclosure follows standard SEC practice by furnishing the release and clarifying its non鈥慺iled status under Section 18.
- SMMT common stock is listed on Nasdaq, confirming exchange registration for the company鈥檚 shares.
- No financial figures or operational metrics are included in the body of the 8-K; readers must consult Exhibit 99.1 for details.
- Filing provides limited incremental information beyond notice that a press release has been issued.
- No material transactions, governance changes, or other substantive disclosures are included in this filing.
Insights
Routine 8-K furnishing a Q2 press release; filing itself lacks financial detail, so limited investor impact.
The filing notifies investors that Summit furnished a press release with second-quarter results and operational updates, but the substantive financial details appear only in the referenced exhibit rather than inline in the 8-K text. As a result, this 8-K serves primarily as a logistics notice that the company has issued a results release; investors must review Exhibit 99.1 for metrics and performance drivers.
Disclosure is standard and procedurally correct; limitation of "filed" status reduces statutory liabilities for the company.
The company follows common practice by furnishing the press release as Exhibit 99.1 and expressly stating it is not "filed" under Section 18. This preserves flexibility and limits certain legal exposures while still making operational and results information publicly available. The 8-K provides no governance changes or material agreements.
Summit Therapeutics Inc. ha comunicato di aver diffuso un comunicato stampa relativo ai risultati finanziari e agli aggiornamenti operativi per il trimestre chiuso il 30 giugno 2025. Il comunicato 猫 allegato come Exhibit 99.1 al presente Current Report ed 猫 richiamato per incorporazione nell'Item 2.02.
Il deposito chiarisce che l'allegato 猫 fornito, non presentato, e pertanto non 猫 soggetto alla responsabilit脿 prevista dalla Sezione 18 e non viene automaticamente incorporato per riferimento in altri documenti ai sensi del Securities Act o dell'Exchange Act, salvo esplicita richiamazione. Le azioni ordinarie della societ脿 sono quotate con il simbolo SMMT sul Nasdaq Stock Market.
Summit Therapeutics Inc. inform贸 que public贸 un comunicado de prensa con sus resultados financieros y avances operativos del trimestre cerrado el 30 de junio de 2025. El comunicado se adjunta como Exhibit 99.1 a este Current Report y se incorpora por referencia en el 铆tem 2.02.
La presentaci贸n aclara que el anexo se est谩 proporcionando, no presentando, y por ello no est谩 sujeto a la responsabilidad prevista en la Secci贸n 18 ni se incorpora autom谩ticamente por referencia en otros documentos amparados por el Securities Act o el Exchange Act, salvo menci贸n expresa. Las acciones ordinarias de la compa帽铆a cotizan bajo el s铆mbolo SMMT en The Nasdaq Stock Market.
Summit Therapeutics Inc.電� 2025雲� 6鞗� 30鞚茧 毵堦皭霅� 攵勱赴鞚� 鞛 鞁れ爜 氚� 鞖挫榿 歆勴枆 靸來櫓鞚� 鞎岆Μ電� 氤措弰鞛愲毳� 氚滍憸頄堧嫟瓿� 氚濏様鞀惦媹雼�. 頃措嫻 氤措弰鞛愲電� 氤� Current Report鞐� Exhibit 99.1搿� 鞝滉车霅橃棃鞙茧┌ 頃 2.02鞐� 鞚橅暣 彀胳“霅橃柎 韽暔霅╇媹雼�.
頃措嫻 鞝滌稖靹滊姅 觳秬氍检澊 鞝滌稖霅� 瓴冹澊 鞎勲媹霛� 鞝滉车霅� 瓴�鞛勳潉 氇呿檿頌� 頃橂┌, 霐半澕靹� 靹轨厴 18鞚� 毂呾瀯 雽�靸侅澊 鞎勲媹瓿� 氇呾嫓鞝� 彀胳“臧� 鞐嗠姅 頃� Securities Act 霕愲姅 Exchange Act鞚� 雼るジ 氍胳劀鞐� 鞛愲彊鞙茧 彀胳“霅橃柎 韽暔霅橃 鞎婌姷雼堧嫟. 須岇偓鞚� 氤错喌欤茧姅 雮橃姢雼� 歃濌秾瓯半灅靻岇棎靹� SMMT 旮绊樃搿� 瓯半灅霅╇媹雼�.
Summit Therapeutics Inc. a d茅clar茅 avoir diffus茅 un communiqu茅 de presse pr茅sentant ses r茅sultats financiers et ses progr猫s op茅rationnels pour le trimestre clos le 30 juin 2025. Le communiqu茅 est fourni en tant que Exhibit 99.1 dans ce Current Report et y est incorpor茅 par r茅f茅rence 脿 l'Item 2.02.
Le d茅p么t pr茅cise que la pi猫ce jointe est fournie, non d茅pos茅e, et n'est donc pas soumise 脿 la responsabilit茅 pr茅vue par la Section 18 et n'est pas automatiquement incorpor茅e par r茅f茅rence dans d'autres documents en vertu du Securities Act ou de l'Exchange Act, sauf renvoi explicite. Les actions ordinaires de la soci茅t茅 sont cot茅es sous le symbole SMMT au Nasdaq.
Summit Therapeutics Inc. gab bekannt, eine Pressemitteilung zu den Finanzergebnissen und operativen Fortschritten f眉r das zum 30. Juni 2025 endende Quartal ver枚ffentlicht zu haben. Die Pressemitteilung ist diesem Current Report als Exhibit 99.1 beigef眉gt und wird durch Verweisung in Punkt 2.02 aufgenommen.
Die Einreichung stellt klar, dass die Anlage bereitgestellt, nicht eingereicht wird und daher nicht der Haftung nach Abschnitt 18 unterliegt und nicht automatisch durch Verweisung in andere Unterlagen gem盲脽 dem Securities Act oder dem Exchange Act einbezogen wird, es sei denn durch ausdr眉ckliche Bezugnahme. Die Stammaktien des Unternehmens werden unter dem Tickersymbol SMMT an der Nasdaq gehandelt.
FAQ
What did Summit Therapeutics (SMMT) report in this 8-K?
Is the press release in this 8-K considered "filed" under Section 18?
Where can I find the actual financial results referenced in the 8-K for SMMT?
Is Summit Therapeutics identified as an emerging growth company in this filing?
On which exchange is Summit Therapeutics' common stock listed and what is the ticker?
